JP Morgan Chase
KTTA icon

JP Morgan Chase’s Pasithea Therapeutics KTTA Stock Holding History

JP Morgan Chase’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107 Hold
150
– – ﹤0.01% 7305
2025
Q4 		$194 Hold
150
– – ﹤0.01% 7160
2025
Q3 		$108 Hold
150
– – ﹤0.01% 7165
2025
Q2 		$108 Hold
150
– – ﹤0.01% 6830
2025
Q1 		$195 Hold
150
– – ﹤0.01% 6802
2024
Q4 		$473 Hold
150
– – ﹤0.01% 6809
2024
Q3 		$813 Hold
150
– – ﹤0.01% 6743
2024
Q2 		$785 Hold
150
– – ﹤0.01% 6643
2024
Q1 		$1.09K Hold
150
– – ﹤0.01% 6641
2023
Q4 		$1.11K Hold
150
– – ﹤0.01% 6824
2023
Q3 		$1.44K Hold
150
– – ﹤0.01% 6594
2023
Q2 		$1.47K Hold
150
– – ﹤0.01% 6392
2023
Q1 		$1K Hold
150
– – ﹤0.01% 6526
2022
Q4 		$2K Buy
150
+100
+200% +$2K ﹤0.01% 6318
2022
Q3 		$1K Hold
50
– – ﹤0.01% 6336
2022
Q2 		$1K Hold
50
– – ﹤0.01% 6360
2022
Q1 		$1K Hold
50
– – ﹤0.01% 6482
2021
Q4 		$2K Buy
+50
New +$2.6K ﹤0.01% 6510

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's KTTA Position: Q1 2026 in Review

JP Morgan Chase held its Pasithea Therapeutics (KTTA) position steady in Q1 2026 at 150 shares worth $107. The position accounts for ﹤0.01% of the portfolio, ranked #7305.

JP Morgan Chase first reported a position in KTTA in Q4 2021 and has held it in 18 quarters since. The position peaked at $2K in Q4 2022. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • JP Morgan Chase held 150 shares of Pasithea Therapeutics worth $107 as of Q1 2026.
  • JP Morgan Chase left its Pasithea Therapeutics share count unchanged in Q1 2026.
  • Pasithea Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7305 holding.
  • JP Morgan Chase first reported a position in Pasithea Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • JP Morgan Chase's Pasithea Therapeutics position peaked at $2K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.